

1 **Delineating the effect of sex hormone intake on immunity in cis and** 2 **trans women with HIV**

3 Chloé Pasin^{1,2,3,*}, David Garcia Nuñez⁴, Katharina Kusejko^{1,2}, Anna Hachfeld⁵, Hélène
4 Buvelot⁶, Matthias Cavassini⁷, Lauro Damonti^{5,8}, Christoph Fux⁹, Begoña Martinez de
5 Tejada¹⁰, Julia Notter¹¹, Alexandra Trkola², Huldrych F. Günthard^{1,2}, Karoline Aebi-
6 Popp^{5,§}, Roger D. Kouyos^{1,2,§}, Irene A. Abela^{1,2,§}, and the Swiss HIV Cohort Study

7

8

9 ¹ Department of Infectious Diseases and Hospital Epidemiology, University Hospital
10 Zurich, University of Zurich, Zurich, Switzerland.

11 ² Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

12 ³ Collegium Helveticum, Zurich, Switzerland.

13 ⁴ Center for Gender Variance, Department of Plastic, Reconstructive, Aesthetic and
14 Hand Surgery, University Hospital Basel, Basel, Switzerland.

15 ⁵ Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland

16 ⁶ Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland

17 ⁷ Division of Infectious Diseases, Lausanne University Hospital, Lausanne, Switzerland

18 ⁸ Ente Ospedaliero Cantonale, Division of Infectious Diseases, Regional Hospital
19 Lugano, Lugano, Switzerland

20 ⁹ Department of Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau,
21 Switzerland

22 ¹⁰ Department of Pediatrics, Gynecology and Obstetrics, University Hospitals of Geneva
23 and Faculty of Medicine, Geneva, Switzerland

24 ¹¹ Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St.
25 Gallen, St. Gallen, Switzerland

26

27 * Corresponding author: chloe.pasin@usz.ch

28 § These authors contributed equally.

29 **Abstract**

30 **Background:** Although sex hormones are recognized to induce immune variations, little
31 is known on the effect of exogenous sex hormone intake on immune responses in cis and
32 trans women. Here, we aimed at quantifying how sex hormone intake affects HIV-1
33 immune markers in cis women (CW) and trans women (TW) with HIV.

34 **Methods:** We considered measurements of key HIV-1 immune markers (CD4, CD8,
35 lymphocyte counts, and CD4:CD8 ratio) from cis men (CM), CW, and TW enrolled in the
36 Swiss HIV Cohort Study. We modeled immune markers using linear mixed-effects models
37 with an interaction between the variables “group” (CW, TW) and “with sex hormone
38 intake” (yes/no). We conducted serum proteomics measurements of 92 inflammation
39 markers on samples from 31 TW before and after sex hormone intake to assess the
40 inflammation environment.

41 **Results:** We included 54'141 measurements from 3'092 CW and 83 TW sampled
42 between 2015 and 2022, and 147'298 from 8'611 CM. Sex hormone intake was
43 associated with significant distinct effects on CD4 and CD4:CD8 ratio between the
44 different groups of women ($p=0.0025$ and 0.015). TW with sex hormone intake had
45 significantly higher CD4 counts (median = 772 (1Q-3Q=520-1'006)) than without (median
46 = 617 (1Q-3Q=426-892)). This increase was similar in magnitude to the difference in CD4
47 counts between CW and CM. None of the serum inflammation proteins showed significant
48 concentration difference before and after sex hormone intake in TW.

49 **Conclusion:** This study highlights the need to consider the potential role of sex hormone
50 intake in modulating the immune system among other biological and social factors,
51 especially in TW in HIV.

52 **Introduction**

53 Sex and gender differences in the immune response have been observed in many
54 settings, and in general women mount more robust cellular and humoral immune
55 responses to infection and vaccination compared to men (1-6). These differences are
56 multifactorial and could be influenced by the immuno-modulatory effect of sex hormones
57 (7-9), with oestrogens having a stimulating effect (10) while testosterone having a
58 suppressive effect on immune function (11). Sex hormones have also shown a multilevel
59 effect on chronic infections such as HIV-1 (12), where women have displayed lower viral
60 loads (13-15) and higher CD4+ T cell counts (16, 17) than men following seroconversion,
61 and higher levels of immune activation (18, 19). Women also tend to have a lower latent
62 HIV-1 reservoir size (20-22) and oestrogens were found to inhibit HIV-1 transcription (23).
63 Although sex hormones could play a role in HIV-1 acquisition risk (24), recent evidence
64 suggest that hormonal contraception does not affect the risk of HIV-1 acquisition (25-28)
65 or disease progression (29, 30).

66 However, the effect of sex hormones intake on HIV-1 immune markers dynamics has
67 been insufficiently explored. Additionally, most of the findings previously mentioned were
68 obtained by studying cis women (CW) versus cis men (“cis” referring to people whose
69 gender identify matches the one assigned at birth), or without specifying this information.
70 Trans women (TW, referring to people who were recorded male at birth but do not identify
71 with being a man) are disproportionally affected by HIV-1 (31, 32) and constitute a distinct
72 epidemiologic group compared to men having sex with men and cis women (32-34). TW
73 are still under-represented in HIV-1 research; therefore, little is known on the immune
74 effect of sex hormone intake in TW and more generally on the effect of hormonal therapy
75 taken by TW on HIV-1 suppression and longer-term health outcomes (35-38). Additionally,
76 concerns on drug-drug interactions between antiretroviral treatment (ART) and sex
77 hormones might limit hormone prescription in women with HIV-1 (39, 40).

78 The aim of this study was to analyze sex hormone intake in CW and TW from the SHCS,
79 and to delineate the effect of sex hormones on key HIV-1 markers in CW and TW with
80 sex hormone intake or not. Furthermore, we aimed to characterize the potential immuno-
81 modulatory effect of sex hormones in TW by measuring inflammatory protein levels before
82 and after sex hormone intake using a high-throughput proteomics assay.

83

84 **Results**

85 **Study population**

86 Participants from the Swiss HIV Cohort Study (SHCS) attend biannual visits during which
87 blood samples are drawn and the following laboratory measurements are realized:
88 number of leucocytes, lymphocytes, CD3+, CD4+, and CD8+ T cells (cells/ μ L), HIV-1 viral
89 load (copies/mL). We considered measurements realized after January 1st, 2015: from
90 that date, the SHCS data contains systematic report of most comedications using the
91 ATC codes nomenclature. We included in the analysis a total of 54'141 laboratory
92 measurements between January 2015 and September 2022 from 954 CW younger than
93 40 years-old (CW<40), 2'365 CW between 40 and 60 years-old (CW 40-60), 573 CW
94 older than 60 years-old (CW>60), and 83 TW (Figure 1). As a comparison we also
95 considered similarly selected 147'298 laboratory measurements from 8'611 cis men.
96 As previously described (33), TW in the SHCS were more likely to be of Asian and
97 Hispano-American ethnicity compared to CW and had overall similar education levels as
98 CW (Table 1). A higher proportion of TW had ever taken sex hormones compared to CW
99 (69.9% versus 18.9%). We observed the highest CD4+ T cell, CD8+ T cell, and
100 lymphocyte counts in TW with sex hormone intake (median respectively 772 cells/ μ L, 822
101 cells/ μ L, and 2288 cells/ μ L), while the CD4:CD8 ratio was the lowest in TW without sex
102 hormone intake (median 0.80) (Table 2, Figure 2, Supplementary Figure 1, 2). CW>60
103 with sex hormone intake had the lowest proportion (0.2%) of samples with detectable viral
104 load (RNA > 50 copies/mL), and TW without sex hormone intake the highest (8.3%). Of
105 note, only a small proportions of viral load measurements in TW without sex hormone
106 intake were above 1'000 copies/mL (1.3%, Supplementary Table 1).

107

108 **Diversity of sex hormone intake in women from the Swiss HIV Cohort Study**

109 Using information contained in the ATC codes, we were able to further differentiate the
110 type of sex hormones taken by women from the SHCS, as well as their route of
111 administration (Table 3, Supplementary Figure 3). CW<40 mostly reported the use of
112 systemic progestogens (35.1%) or combined oestrogens and progestogens (36.9%), in
113 line with the use of hormonal contraception (HC). CW>60 mostly reported the use of local

114 oestrogens (63.2%) or systemic combined oestrogens and progestogens (21.1%),
115 corresponding to the use of menopause hormone therapy (MHT). In the group of CW 40-
116 60, we observed more heterogeneity, with reports of HC use (systemic combined
117 oestrogens and progestogens, 38.4%, and systemic progestogens, 21.1%) but also MHT
118 (systemic and local oestrogens, respectively 17.6% and 14.5%), reflecting the potential
119 overlap of contraception with the need for managing symptoms during perimenopause.
120 Finally, TW mostly reported the use of oestrogens (53.2%) or combined oestrogens and
121 antiandrogens (32.9%). Our descriptive analysis highlighted the diversity of sex hormone
122 intake in women from the SHCS and the complexity of the data when assessing and
123 comparing different age groups.

124

125 **Sex hormone intake is associated with distinct effects on immune markers in CW** 126 **and TW with HIV**

127 We assessed the effects of sex hormone intake on immune markers by using linear
128 mixed-effect models adjusted for potential confounders such as years since ART start,
129 ethnicity, intravenous drug use, education level, and age (Figure 3, Supplementary Figure
130 4). We found significantly different effects of sex hormone intake on CD4 and CD4:CD8
131 ratio between the studied groups (CW<40, CW 40-60, CW>60, and TW) (interaction
132 $p^{CD4}=0.02$, $p^{ratio}=0.007$). Interestingly, we found a significant increase of CD4 counts,
133 CD4:CD8 ratio, and lymphocyte counts associated with sex hormone intake in TW (effect
134 on the scaled outcomes = 0.19, 95% confidence interval [0.10,0.28] for CD4 counts, 0.08
135 [0.02,0.15] for CD4:CD8 ratio, and 0.15 [0.04,0.25] for lymphocytes counts). CD4 and
136 lymphocyte counts displayed high correlation in TW (Pearson $r=0.78$, $p<0.001$,
137 Supplementary Figure 5), suggesting that the increase in lymphocyte counts in TW with
138 sex hormone intake was mostly due to the observed increase in CD4 counts.

139 Chronic viral and bacterial infections and lifestyle factors such as smoking could have an
140 impact on immune markers (41-43). We conducted sensitivity analyses adjusted on
141 smoking status and co-infection with hepatitis C and/or syphilis and found consistent
142 results on the effect of sex hormones on immune markers (Supplementary Figure 6). We
143 further investigated whether changes in immune markers could be linked to viral control,
144 adherence to ART, and/or mental health problems. Interestingly, sex hormone intake was

145 significantly correlated with undetectable or suppressed viral load in both CW and TW
146 (chi square test $p < 0.001$ for $CW < 40$, $CW > 60$, and TW, and $p = 0.002$ for CW 40-60,
147 Supplementary Table 1), with better self-reported adherence in $CW < 40$ (chi square test
148 $p < 0.001$) and CW 40-60 (chi square test $p < 0.001$), but with more depression in $CW < 40$
149 (chi square test $p = 0.025$). When adjusting for depression, self-reported adherence, and
150 viral load, the increase of CD4 counts in TW upon sex hormone intake remained
151 significant (effect on the scaled outcome = 0.14 [0.05,0.23], Supplementary Figure 7),
152 suggesting that this increase cannot solely be explained by better adherence to treatment
153 and control of the virus.

154 We further investigated whether the effects of sex hormones on immune markers in CW
155 and TW were comparable to the differences in immune marker levels between cis men
156 and CW (Supplementary Figure 8). Interestingly, the size of the effect of sex hormones
157 on CD4 counts in TW was very similar to the difference of CD4 counts in CW (without sex
158 hormone intake) versus cis men (CM, effect on the scaled outcome = 0.19 [0.14,0.24]).
159 However, the effect on CD8 counts and lymphocytes was different, suggesting that sex
160 and gender differences in immune markers cannot fully be compared to the inferred effect
161 of exogenous sex hormone intake in CW and TW.

162 Considering the diversity of sex hormones taken by the population of women in the SHCS,
163 we also investigated the effect of different type and route of hormones among the defined
164 groups (Figure 4). Among TW taking sex hormones, we found trends for lower CD4, CD8,
165 and lymphocyte counts in TW with combinations of oestrogens and antiandrogens versus
166 TW taking oestrogens only ($p^{CD4} = 0.075$, $p^{CD8} = 0.052$, and $p^{lymphocytes} = 0.090$). Among
167 $CW < 40$ taking sex hormones, we observed significantly lower CD8 and lymphocyte
168 counts and higher CD4:CD8 ratio ($p^{CD8} = 0.050$, $p^{lymphocyte} = 0.015$, $p^{ratio} = 0.004$ respectively)
169 among those taking progestogens only versus those taking oestrogens and progestogens
170 in combination.

171
172 **No evidence for inflammatory pathways activation upon sex hormone intake in TW**

173 We further sought to identify whether sex hormone intake had an anti-inflammatory effect
174 in TW (44). To do so, we assessed the effect of sex hormone intake on immunity in 31
175 TW (19 taking oestrogens only and 12 taking a combination of oestrogens and

176 antiandrogens) by undertaking a targeted proteomic analysis of individual soluble
177 inflammation-associated proteins in two sequential samples: one taken up to 2 years
178 before the start of sex hormone intake (median 176 days, 1Q-3Q = 58-240 days) and one
179 taken between 1 and 18 months after the start of sex hormone intake (median 175 days,
180 1Q-3Q = 155-225 days). Using an unsupervised hierarchical clustering strategy, we found
181 no distinct immune signature between the samples taken before and after sex hormone
182 intake (Supplementary Figure 9). After adjustment for multiple testing, we found no
183 significant differential protein concentration in TW before and after sex hormone intake
184 (Supplementary Table 2). Only two proteins displayed significant changes when
185 considering the p-value unadjusted for multiple testing, namely neurotrophin-3 (NT-3,
186 $p=0.019$) and STAMBP ($p=0.032$), for which we observed a decreased concentration
187 upon sex hormone intake (Supplementary Figure 10).

188

189 **Discussion**

190 We report here on the first large cohort study analyzing the impact of exogenous sex
191 hormone intake on the immune system in women with HIV. Our study explicitly included
192 TW in the analysis to gain insights into effects of sex hormone intake on the immune
193 system in a population often understudied in HIV-1 research.

194 Although rates of MHT intake in menopausal cis women were previously reported in the
195 SHCS (45), we were now able to extensively describe the diversity of sex hormones taken
196 by women in the SHCS. Notably, our analysis highlighted the complexity of the
197 menopausal transition, during which the need of HC and MHT are likely to overlap.

198 Based on a number of studies partially attributing sex and gender differences in immunity
199 to the role of sex hormones (1-5, 16), we investigated how exogenous sex hormone intake
200 affect major HIV-1 immune markers. Observed differences of sex hormone intake on
201 immune markers (CD4, CD4:CD8 ratio) in CW and TW could be due to differences in the
202 combination of hormones taken. Indeed, TW mostly reported intake of oestrogens and/or
203 antiandrogens and CW mostly reported intake of oestrogens and/or progestogens,
204 depending on their age. Additionally, within each group, we did observe significant (in
205 CW<40) or trends (in TW) of differential effects on HIV-1 markers by type of sex hormone.

206 Differences in dosing and mechanisms of actions of sex hormones on the immune system
207 in CW and TW could also explain our results and should be further investigated.

208 Our most robust result was the significant association between sex hormone intake and
209 an increase in CD4 counts in TW. This increase was similar in magnitude to the difference
210 of CD4 counts between CW (not taking sex hormones) and CM, but this similarity was
211 not identified for the other markers (CD8, CD4:CD8 ratio, lymphocytes). In line with
212 previous work (46-48), this highlights the complexity and variety of factors (chromosomal,
213 hormonal, and social) playing a role in immune modulation.

214 Additionally, we explored how factors such as adherence and mental health could play a
215 role in our analyses. Indeed, it has been reported that sex hormone intake in TW can be
216 associated with lower adherence to ART, driven by concerns of drug-drug interactions
217 (38, 39, 49). However, access to gender-affirming hormone therapy in TW was also
218 shown to be associated with overall better mental health (50-52), which is known to be a
219 good predictor for adherence in people with HIV (53-56). In our analysis, we did not find
220 any association in TW between sex hormone intake and self-reported adherence to ART
221 or depression. Even after adjusting for these variables, we still found a significant increase
222 in CD4 counts with sex hormone intake in TW, suggesting that other social and biological
223 factors are potentially responsible for this increase. However, we did identify a correlation
224 between depression and HC in CW<40, in line with previous reports (57-59). Although
225 previous results showed that mental health was not associated with adherence to ART or
226 viral suppression during menopausal transition (60), more studies are needed in CW and
227 TW with HIV to investigate the interplay between sex hormone intake, mental health, and
228 immunity.

229 Using a high-throughput serum proteomics approach, we aimed at identifying the
230 inflammatory pathways potentially modulated with sex hormone intake in TW. We could
231 not identify any proteins with significant concentration change before and after sex
232 hormone intake in TW after adjusting for multiple testing. This negative result could be
233 due to our low sample size or to the timing of the sampling before and after the start of
234 sex hormone intake. Indeed, a previous report found that inflammatory markers were only
235 transiently modified in TW receiving oral oestrogens, with a return to baseline levels
236 between 2 to 6 months after the start of oestrogens intake (61). As the samples retrieved

237 from our biobank were obtained with a median of around 6 months after the start of sex
238 hormone intake, we cannot exclude that this time window was not allowing us to identify
239 transient inflammatory changes happening earlier after the start of sex hormone intake.
240 Although all our statistical analyses were adjusted for confounders and we conducted
241 several sensitivity analyses, this study is observational by design, and it is therefore not
242 possible to definitely conclude on the causality between sex hormone intake and increase
243 of CD4+ T cell counts in TW. Our analysis did not include longitudinal modeling of immune
244 trajectories, preventing us to draw final conclusions on the time between start of sex
245 hormone intake and potential modulations of immune markers. However, measurements
246 at more regular and specific timepoints would be required to address this question.
247 Additionally, we only observed the total number of cells, and the cohort design does not
248 include any phenotyping of cells, which is preventing us to conclude on the cell subtypes
249 with increased population with sex hormone intake.
250 In conclusion, our results present new insights on the effect of exogenous sex hormone
251 intake on the immune system of cis and trans women with HIV and highlights the need to
252 consider the potential role of sex hormones in modulating the immune system among
253 other biological and social factors.

254

255 **Methods**

256 **Swiss HIV Cohort Study**

257 The Swiss HIV Cohort Study (SHCS) is a prospective multicenter cohort study enrolling
258 people with HIV in Switzerland (62). The SHCS was approved by the local ethical
259 committees of the participating centers, and written informed consent was obtained from
260 all participants. Participants are followed-up biannually with data collection including
261 behavioral information, drug intake, gynecological exam if applicable. Blood samples are
262 systematically drawn at each visit for laboratory measurements and storage in a biobank.
263 In the main analysis, we considered laboratory measurements from samples drawn in
264 CW and TW after January 1st, 2015, when systemic report of most comedications taken
265 by SHCS participants started. Reports include (since 2015) ATC codes, drug brand, dose,
266 and route of administration for both antiretrovirals and co-medication. We excluded from
267 the analysis laboratory measurements that were sampled when participants were not on

268 ART, less than 3 months after the first start of ART intake, during pregnancies, and during
269 hormone intake as subsequent treatment for bacterial vaginosis or treatment for
270 endometriosis (as these conditions could themselves be associated with changes in
271 immunity).

272 As a comparison we also considered laboratory measurements in 147'298 samples on
273 ART for at least 3 months from 8'611 cis men after January 1st, 2015.

274

275 **Cis and trans women in the SHCS**

276 We identified 86 TW – using criteria previously described (33), and 3'165 CW with at least
277 one laboratory measurement after January 1st, 2015.

278

279 **Sex hormone intake definition**

280 Sex hormone intake was assessed using the following ATC codes: G02BA03 (hormonal
281 intrauterine contraceptive with progestogens), G02BB (contraceptive vaginal ring with
282 oestrogens and progestogens in combination), G03A (hormonal contraceptive for
283 systemic use), G03C (oestrogens), G03D (progestogens), G03E (androgens and female
284 sex hormone in combination), and G03F (progestogens and oestrogens in combination).
285 For each ATC code, report of the start and end of the corresponding drug are indicated.
286 Sex hormone reports for each participant were obtained by combining different sex
287 hormones when taken at the same time (Supplementary Figure 3), then classified by the
288 type (e.g., oestrogens, progestogens, oestrogens + antiandrogens) and route (e.g.,
289 systemic, local) of intake. For example, a participant's report with a simultaneous intake
290 of a product with ATC code G03CA (transdermal, oestrogens) and another product with
291 ATC code G03AC (systemic, progestogens) will be classified as systemic oestrogens +
292 progestogens.

293 Measurements that were realized on blood samples drawn during the period of sex
294 hormone intake were labeled as “with sex hormone intake”, others “without sex hormone
295 intake”.

296

297 **Smoking, depression, and adherence definition**

298 Information on smoking, depression, and self-reported adherence to ART (obtained
299 during bi-annual visits) were linked to laboratory measurements realized up to 6 months
300 before the corresponding follow-up visit.

301

302 **Proteomics measurements**

303 We retrieved plasma samples from the SHCS biobank: we selected 31 TW for which
304 plasma samples were available both before the first reported start of sex hormone intake
305 (between one month and two years) and after it (between three months and two years),
306 with no reported interruption between the start of intake and the plasma collection.
307 Proteomics measurements were realized on the 62 retrieved samples using the Olink®
308 Target 96 technology Inflammation panel (63), which enables high-throughput, multiplex
309 immunoassays by measuring up to 92 proteins across 96 plasma samples simultaneously
310 (Olink Bioscience AB, Uppsala, Sweden). Olink® Target 96 is based on the Proximity
311 Extension Assay (PEA). Using oligonucleotide-labeled antibody probe pairs, PEA permits
312 simultaneous assessment of multiple proteins, maintaining the precision of dual epitope
313 ELISA without the loss of specificity of earlier generation multiplex assays. Signal
314 production requires both recognition of DNA barcoding from sequence-specific
315 oligonucleotides and dual recognition of correctly matched antibody pairs. The PEA assay
316 reports fold change in \log_2 (Normalized Protein eXpression [NPX]) units. The
317 Inflammation panel informs on factors involved in cell differentiation and cytokine-
318 mediated signaling pathways.

319

320 **Statistical analysis**

321 Studied outcomes (CD4+ T cell count, CD8+ T cell count, CD4:CD8 ratio, and total
322 lymphocyte count) were transformed using square-root transformation for the cell counts
323 and log transformation for the ratio, and then scaled. Each outcome was then expressed
324 using a linear mixed effect model with fixed effects for the adjustment variable and a
325 random effect for the individuals to account for repeated measurements. The linear mixed
326 effect model can be written as follows:

$$327 \quad y_{ij} = \sum_{k=1}^n \beta_k x_{kij} + b_i + \varepsilon_{ij}$$

328 Where y_{ij} is the j^{th} observation of participant i , x_k is the k^{th} of n fixed effects (variable of
329 adjustment) and β_k its corresponding coefficient, b_i is the participant-specific normally
330 distributed random effect and ε_{ij} the normally distributed residual error.

331 For the fixed effect, we included a "group" variable (CW<40, CW 40-60, CW>60, TW) and
332 a variable "with sex hormone intake" (yes, no). We considered CW in different age groups
333 due to the strong correlation between the type of sex hormones used and the age of CW
334 (i.e., CW<40 mostly take hormonal contraception, CW>60 mostly take hormonal
335 replacement therapy, while the hormones taken by CW 40-60 are more heterogeneous).
336 We tested whether the sex hormone intake was associated to the outcome differentially
337 in the respective groups by estimating an interaction between the group variable and the
338 sex hormone intake variable. The reference category was CW 40-60, as this was the
339 group with the biggest sample size. We assessed the significance of the interaction term
340 using a likelihood ratio test (complete model with interaction term, reduced model without
341 interaction term). We report the effect of sex hormone intake in the different groups on
342 the scaled outcomes and p-value of the likelihood ratio test for the interaction term. To
343 control for potential confounders, we adjusted the models on the following variables: age
344 at time of sample (continuous with splines), ethnicity, education level, time since ART
345 start (continuous with splines), use of intravenous drugs. In sensitivity analyses, we also
346 adjusted for depression, smoking status at time of sampling, self-reported adherence
347 (three categories: never missed, missed once a month, and missed more than once every
348 two weeks) and viral load (three categories: below 50 copies/mL, 50-1'000 copies/mL
349 and >1'000 copies/mL).

350 Given the left-censored nature of the proteomics data, the analysis was conducted in two
351 steps: we first pre-selected proteins of interest, by excluding those with a proportion of
352 censored values among the 62 samples more than 75%, and a dispersion value (standard
353 deviation divided by the mean value) less than 5%. We then tested for differences
354 between pre and post sex hormone intake samples using paired t-tests. Paired t-tests in
355 proteins with left-censored data were realized using the function `cen_paired` from the
356 NADA2 R package. These analyses were conducted on all samples, on the subset of
357 samples in participants taking oestrogens only, and on the subset of samples in

358 participants taking a combination of oestrogens and anti-androgens. Multiple testing was
359 corrected using the FDR method.

360

361 **Figure 1:** Flow chart of laboratory measurements selection and repartition in the different
362 subgroups. N corresponds to the number of samples with lab measurements, n
363 corresponds to the number of SHCS participants (one participant can have several
364 samples with lab measurements included in the analysis and can contribute to both the
365 no hormone intake and hormone intake groups).

366
367 **Figure 2:** Distribution of CD4+ and CD8+ T cell counts in the different studied populations:
368 CW aged 40 and younger (purple), CW 40-60 years-old (red), CW older than 60 years-
369 old (orange), TW (green) and cis men (CM, black). Dashed line corresponds to the
370 median among all measurements (CD4=657 cells/ μ L, CD8=715 cells/ μ L). For display
371 purposes, 34 measurements (CD4>2500 cells/ μ L) and 77 measurements (CD8>3500
372 cells/ μ L) were excluded from the plot. Individual data points are shown in addition in
373 Supplementary Figure 2.

374
375 **Figure 3:** Effect of sex hormone intake in CW<40 (purple), CW 40-60 (red), CW>60
376 (orange), and TW (green) on the scaled studied outcomes: CD4 counts, CD8 counts,
377 CD4:CD8 ratio and lymphocytes counts. Models were adjusted for potential confounders
378 such as years since first start of ART, ethnicity, intravenous drug use, education level,
379 and age.

380
381 **Figure 4:** Effect of different type and route of hormones on immune markers: in green,
382 comparison of TW taking oestrogens + androgens versus oestrogens only; in purple,
383 comparison of CW<40 taking progestogens versus oestrogens+progestogens; in orange,
384 comparison of CW>60 taking local oestrogens versus systemic oestrogen+progestogens.
385 Models were adjusted for potential confounders such as years since first start of ART,
386 ethnicity, intravenous drug use, education level, and age.

387
388

389 **Table 1:** Description of the population of cis women (CW) and trans women (TW) for
 390 which samples were included in the analysis

	CW	TW	Overall
Sample size	n=3092	n=83	n=3175
Age in 2022:			
median (min,max)	53 (18,95)	45 (21,75)	53 (18,95)
Ethnicity: n(%)			
White	1642 (53.1%)	36 (43.4%)	1678 (52.9%)
Black	1103 (35.7%)	5 (6.0%)	1108 (34.9%)
Hispano-american	104 (3.4%)	16 (19.3%)	120 (3.8%)
Asian	227 (7.3%)	25 (30.1%)	252 (7.9%)
Other/unknown	14 (0.5%)	1 (1.2%)	15 (0.5%)
Missing	2 (0.1%)	0 (0%)	2 (0.1%)
Education: n(%)			
Less than bachelor	2329 (75.3%)	63 (75.9%)	2392 (75.3%)
Bachelor and more	635 (20.5%)	18 (21.7%)	653 (20.6%)
Other/unknown	47 (1.5%)	2 (2.4%)	49 (1.5%)
Missing	81 (2.6%)	0 (0%)	81 (2.6%)
IVD use: n(%)			
No	2549 (82.4%)	80 (96.4%)	2629 (82.8%)
Yes	518 (16.8%)	3 (3.6%)	521 (16.4%)
Missing	25 (0.8%)	0 (0%)	25 (0.8%)
Has taken sex hormones at least once since 2015: n(%)			
No	2509 (81.1%)	25 (30.1%)	2534 (79.8%)
Yes	583 (18.9%)	58 (69.9%)	641 (20.2%)

391

392 **Table 2:** Description of lab measurements (CD4, CD8, and lymphocyte counts, CD4:CD8 ratio, detectable viral load) from
 393 the samples included in the statistical analysis. For each marker the number of measurements available (N) is displayed.
 394

Under sex hormone	CW < 40		CW 40-60		CW > 60		TW		CM
	No	Yes	No	Yes	No	Yes	No	Yes	
Total sample size (N)	9730	1308	32030	3279	5786	618	637	753	147298
Age at sample time:	36 (32,38)	35 (30,38)	51 (46,55)	51 (45,55)	66 (63,71)	67 (62,76)	45 (38,52)	42 (37,50)	52 (44,59)
CD4 (cells/uL) (N)	8118	1108	27395	2805	5006	509	532	631	124823
median (Q1,Q3)	649 (480,861)	715 (557,954)	672 (488,887)	720 (548,929)	663 (477,878)	720 (580,893)	617 (426,892)	772 (520,1006)	651 (480,851)
CD8 (cells/uL) (N)	8064	1103	27194	2793	5001	494	531	616	123685
median (Q1,Q3)	674 (507,899)	656 (489,880)	675 (491,913)	651 (468,882)	656 (459,900)	557 (387,866)	755 (583,975)	822 (609,1033)	732 (534,996)
CD4:CD8 ratio (N)	8064	1103	27190	2793	5001	494	531	616	123679
median (Q1,Q3)	1.00 (0.70,1.35)	1.16 (0.81,1.54)	1.01 (0.71,1.39)	1.14 (0.82,1.59)	1.03 (0.67,1.50)	1.25 (0.92,1.76)	0.84 (0.56,1.12)	0.94 (0.69,1.22)	0.89 (0.62,1.24)
Lymphocytes (cells/uL) (N)	7974	1096	26670	2663	4812	487	525	618	121563
median (Q1,Q3)	1873 (1500,2332)	1908 (1529,2398)	1900 (1500,2400)	1937 (1569,2400)	1900 (1476,2395)	1870 (1558,2364)	2082 (1700,2581)	2288 (1768,2866)	1949 (1548,2421)
HIV-1 VL (copies/mL) (N)	9586	1288	31270	3212	5689	612	612	745	144228
Detectable VL (>50): n(%)	698 (7.2%)	45 (3.4%)	1499 (4.7%)	92 (2.9%)	256 (4.4%)	1 (0.2%)	53 (8.3%)	12 (1.6%)	6078 (4.1%)

395

396 **Table 3:** Description of sex hormones intake reported by women in the SHCS. Sex
 397 hormone reports are defined as explained in the supplementary figure 3. Total number
 398 of sex hormone reports in each group are displayed (n).
 399
 400

		CW<40 n=390	CW 40-60 n=620	CW>60 n=76	TW n=158
Oestrogens	Systemic	13 (3.3%)	109 (17.6%)	8 (10.5%)	84 (53.2%)
	Local	8 (2.1%)	90 (14.5%)	48 (63.2%)	0
	Systemic & local	0	2 (0.3%)	2 (2.6%)	0
Progestogens	Systemic	137 (35.1%)	131 (21.1%)	2 (2.6%)	4 (2.5%)
	Local	55 (14.1%)	28 (4.5%)	0	0
	Systemic & local	3 (0.8%)	0	0	0
Oestrogens + Progestogens	Systemic	144 (36.9%)	238 (38.4%)	16 (21.1%)	2 (1.3%)
	Local	8 (2.1%)	3 (0.5%)	0	0
	Systemic & local	3 (0.8%)	7 (1.1%)	0	0
Antiandrogens	Systemic	0	1 (0.2%)	0	7 (4.4%)
Oestrogens + Antiandrogens	Systemic	17 (4.4%)	9 (1.5%)	0	52 (32.9%)
Oestrogens + Androgens	Systemic	0	2 (0.3%)	0	5 (3.2%)
Oestrogens + Antiandrogens + Androgens	Systemic	0	0	0	3 (1.9%)
Oestrogens + Progestogens + Antiandrogens	Systemic	2 (0.5%)	0	0	1 (0.6%)

401

402 **Acknowledgments.** We thank the participants of the SHCS, the physicians and study
403 nurses for excellent patient care, and the SHCS data center for excellent data
404 management.

405
406 **Members of the Swiss HIV Cohort Study:** Abela I, Aebi-Popp K, Anagnostopoulos A,
407 Battegay M, Bernasconi E, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A,
408 Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF
409 (President of the SHCS), Hachfeld A, Haerry D (deputy of "Positive Council"), Hasse B,
410 Hirsch HH, Hoffmann M, Hösli I, Huber M, Jackson-Perry D (patient representatives),
411 Kahlert CR (Chairman of the Mother & Child Substudy), Kaiser L, Keiser O, Klimkait T,
412 Kouyos RD, Kovari H, Kusejko K (Head of Data Centre), Labhardt N, Leuzinger K,
413 Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nemeth J, Nicca D, Notter J,
414 Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the Scientific Board), Salazar-
415 Vizcaya L, Schmid P, Speck R, Stöckle M (Chairman of the Clinical and Laboratory
416 Committee), Tarr P, Trkola A, Wandeler G, Weisser M, Yerly S.

417
418 **Financial support.** This work has been financed within the framework of the Swiss HIV
419 Cohort Study, supported by the Swiss National Science Foundation (grant #201369), by
420 SHCS project #882 and by the SHCS research foundation. The data were gathered by
421 the 5 Swiss university hospitals, 2 cantonal hospitals, 15 affiliated hospitals, and 36
422 private physicians (listed at <http://www.shcs.ch/180-health-care-providers>). IAA is
423 supported by a research grant of the Promedica Foundation. CP is supported by a
424 Fellowship from the Collegium Helveticum.

425
426 **Potential conflicts of interests.**
427 IAA has received honoraria from MSD and Sanofi, a travel grant from Gilead Sciences,
428 and a grant from the Promedica foundation. RDK has received research fundings from
429 Gilead unrelated to this work. AH's institution has received travel grants, congress and
430 advisory fees from MSD, Viiv and Gilead, unrelated to this work. KAP's institution has
431 received travel grants and advisory fees from MSD, Gilead and ViiV healthcare unrelated
432 to this work. HFG has received grants from the SNF; SHCS; Yvonne Jacob Foundation;

433 University of Zurich's Clinical Research Priority Program, viral disease; Zurich Primary
434 HIV Infection; Systems.X; National Institutes of Health; Gilead Sciences; and Roche; and
435 personal fees from Merck, Gilead Sciences, ViiV, GSK, Janssen, Johnson and Johnson
436 and Novartis, for consultancy or DSMB membership and a travel grant from Gilead.

437
438 **Authors contribution.** CP, RDK: conception and design of the study, analysis and
439 interpretation of data, drafting and revision of the article. IAA: conception and design of
440 the study, acquisition of data, analysis and interpretation of data, drafting and revision of
441 the article. KAP: acquisition of data, analysis and interpretation of data, drafting and
442 revision of the article. All other co-authors: acquisition of data, drafting and revision of the
443 article.

444
445 **Data availability.** The individual level datasets generated or analyzed during the current
446 study do not fulfill the requirements for open data access:

447 1) The SHCS informed consent states that sharing data outside the SHCS network is only
448 permitted for specific studies on HIV infection and its complications, and to researchers
449 who have signed an agreement detailing the use of the data and biological samples; and
450 2) the data is too dense and comprehensive to preserve patient privacy in persons living
451 with HIV.

452 According to the Swiss law, data cannot be shared if data subjects have not agreed or
453 data is too sensitive to share. Investigators with a request for selected data should send
454 a proposal to the respective SHCS address (www.shcs.ch/contact). The provision of
455 data will be considered by the Scientific Board of the SHCS and the study team and is
456 subject to Swiss legal and ethical regulations, and is outlined in a material and data
457 transfer agreement.

458
459

- 460 1. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males:
461 implications for vaccine efficacy. *Current opinion in physiology*. 2018;6:16-20.
- 462 2. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the
463 Outcomes of Vaccination over the Life Course. *Annual Review of Cell and Developmental*
464 *Biology*. 2017;33(1):577-99.
- 465 3. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*.
466 2016;16(10):626-38.
- 467 4. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines.
468 *Lancet Infect Dis*. 2010;10(5):338-49.
- 469 5. Lotter H, Altfeld M. Sex differences in immunity. *Semin Immunopathol*. 2019;41(2):133-
470 5.
- 471 6. Markle JG, Fish EN. SeXX matters in immunity. *Trends Immunol*. 2014;35(3):97-104.
- 472 7. Taneja V. Sex Hormones Determine Immune Response. *Front Immunol*. 2018;9:1931.
- 473 8. Moulton VR. Sex Hormones in Acquired Immunity and Autoimmune Disease. *Front*
474 *Immunol*. 2018;9:2279.
- 475 9. Ortona E, Pierdominici M, Rider V. Editorial: Sex Hormones and Gender Differences in
476 Immune Responses. *Frontiers in Immunology*. 2019;10(1076).
- 477 10. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. *Clin Rev*
478 *Allergy Immunol*. 2011;40(1):66-73.
- 479 11. Furman D, Hejblum BP, Simon N, Jovic V, Dekker CL, Thiebaut R, Tibshirani RJ, Davis
480 MM. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in
481 the response to influenza vaccination. *Proc Natl Acad Sci U S A*. 2014;111(2):869-74.
- 482 12. Rechten A, Altfeld M. Sexual dimorphism in HIV-1 infection. *Seminars in*
483 *Immunopathology*. 2019;41(2):195-202.
- 484 13. Napravnik S, Poole C, Thomas JC, Eron JJ, Jr. Gender difference in HIV RNA levels: a
485 meta-analysis of published studies. *J Acquir Immune Defic Syndr*. 2002;31(1):11-9.
- 486 14. Ruel TD, Zanoni BC, Ssewanyana I, Cao H, Havlir DV, Kanya M, Achan J, Charlebois
487 ED, Feeney ME. Sex Differences in HIV RNA Level and CD4 Cell Percentage During Childhood.
488 *Clinical Infectious Diseases*. 2011;53(6):592-9.
- 489 15. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial
490 Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. *New England Journal*
491 *of Medicine*. 2001;344(10):720-5.
- 492 16. Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. *J Infect Dis*.
493 2014;209 Suppl 3:S86-92.
- 494 17. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS,
495 Shafer RW, Robbins GK, Pollard RB, Team A. Effect of Baseline- and Treatment-Related Factors
496 on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects:
497 Results From ACTG 384. *JAIDS Journal of Acquired Immune Deficiency Syndromes*.
498 2006;42(4):426-34.
- 499 18. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Lindsay RJ,
500 Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins
501 GK, Altfeld M. Sex differences in the Toll-like receptor-mediated response of plasmacytoid
502 dendritic cells to HIV-1. *Nat Med*. 2009;15(8):955-9.
- 503 19. El-Badry E, Macharia G, Claiborne D, Brooks K, Dilernia DA, Goepfert P, Kilembe W,
504 Allen S, Gilmour J, Hunter E. Better Viral Control despite Higher CD4+ T Cell Activation during

- 505 Acute HIV-1 Infection in Zambian Women Is Linked to the Sex Hormone Estradiol. *Journal of*
506 *Virology*. 2020;94(16):e00758-20.
- 507 20. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N,
508 Bogojeska J, Fellay J, Roth V, Kok YL, Thorball CW, Borghesi A, Parbhoo S, Wieser M, Boni J,
509 Perreau M, Klimkait T, Yerly S, Battegay M, Rauch A, Hoffmann M, Bernasconi E, Cavassini M,
510 Kouyos RD, Gunthard HF, Metzner KJ, the Swiss HIV Cohort Study. Determinants of HIV-1
511 reservoir size and long-term dynamics during suppressive ART. *Nat Commun*. 2019;10(1):3193.
- 512 21. Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A,
513 Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M,
514 Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG. Sex-Based Differences in
515 Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. *The*
516 *Journal of Infectious Diseases*. 2018;219(7):1084-94.
- 517 22. Gianella S, Rawlings SA, Dobrowolski C, Nakazawa M, Chaillon A, Strain M, Layman L,
518 Caballero G, Scully E, Scott B, Pacis C, Weber KM, Landay A, Anderson C, Karn J. Sex
519 Differences in Human Immunodeficiency Virus Persistence and Reservoir Size During Aging.
520 *Clinical Infectious Diseases*. 2022;75(1):73-80.
- 521 23. Das B, Dobrowolski C, Luttge B, Valadkhan S, Chomont N, Johnston R, Bacchetti P, Hoh
522 R, Gandhi M, Deeks SG, Scully E, Karn J. Estrogen receptor-1 is a key regulator of HIV-1 latency
523 that imparts gender-specific restrictions on the latent reservoir. *Proc Natl Acad Sci U S A*.
524 2018;115(33):E7795-E804.
- 525 24. Scully EP. Sex Differences in HIV Infection. *Current HIV/AIDS Reports*. 2018;15(2):136-
526 46.
- 527 25. Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-
528 Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S,
529 Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-
530 Jones D, van de Wijgert JH, Stalter R, Low N. Hormonal contraception and the risk of HIV
531 acquisition: an individual participant data meta-analysis. *PLoS Med*. 2015;12(1):e1001778.
- 532 26. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk
533 of HIV acquisition: a meta-analysis of observational studies. *Lancet Infect Dis*. 2015;15(2):181-9.
- 534 27. Curtis KM, Hannaford PC, Rodriguez MI, Chipato T, Steyn PS, Kiarie JN. Hormonal
535 contraception and HIV acquisition among women: an updated systematic review. *BMJ Sexual &*
536 *Reproductive Health*. 2020;46(1):8-16.
- 537 28. Ahmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D, Gichangi PB,
538 Heller KB, Hofmeyr GJ, Justman J, Kasaro MP, Kiarie J, Louw C, Mastro TD, Morrison CS,
539 Mugo NR, Nair G, Nanda K, Nhlabatsi Z, Onono M, Palanee-Phillips T, Pleaner M, Rees H,
540 Singata-Madliki M, Scoville CW, Selepe RAP, Shears K, Sibiyi S, Smit J, Steyn PS, Stringer J,
541 Taylor D, Thomas KK, Welch JD. HIV incidence among women using intramuscular depot
542 medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for
543 contraception: a randomised, multicentre, open-label trial. *The Lancet*. 2019;394(10195):303-13.
- 544 29. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV
545 disease progression: a systematic review. *AIDS*. 2013;27(5):787-94.
- 546 30. Whiteman MK, Jeng G, Samarina A, Akatova N, Martirosyan M, Kissin DM, Curtis KM,
547 Marchbanks PA, Hillis SD, Mandel MG, Jamieson DJ. Associations of hormonal contraceptive
548 use with measures of HIV disease progression and antiretroviral therapy effectiveness.
549 *Contraception*. 2016;93(1):17-24.

- 550 31. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden
551 of HIV in transgender women: a systematic review and meta-analysis. *The Lancet Infectious*
552 *Diseases*. 2013;13(3):214-22.
- 553 32. Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global Epidemiology of HIV Infection
554 and Related Syndemics Affecting Transgender People. *JAIDS Journal of Acquired Immune*
555 *Deficiency Syndromes*. 2016;72.
- 556 33. Nguyen H, Hampel B, Garcia Nuñez D, Battegay M, Hachfeld A, Bernasconi E, Calmy A,
557 Cavassini M, Vernazza P, Fellay J, Rudolph H, Huber M, Leuzinger K, Perreau M, Scherrer A,
558 Ramette AN, Yerly S, Günthard HF, Kouyos RD, Kusejko K, the Swiss HIV Cohort Study.
559 Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an
560 Epidemiologically Distinct Risk Group. *Clinical Infectious Diseases*. 2021.
- 561 34. Stahlman S, Liestman B, Ketende S, Kouanda S, Ky-Zerbo O, Lougue M, Diouf D, Anato
562 S, Tchalla J, Bamba A, Drame FM, Ezouatchi R, Kouamé A, Baral SD. Characterizing the HIV
563 risks and potential pathways to HIV infection among transgender women in Côte d'Ivoire, Togo
564 and Burkina Faso. *Journal of the International AIDS Society*. 2016;19(3S2):20774.
- 565 35. Gianella S, Sonya Haw J, Blumenthal J, Sullivan B, Smith D. The Importance of Human
566 Immunodeficiency Virus Research for Transgender and Gender-Nonbinary Individuals. *Clin*
567 *Infect Dis*. 2018;66(9):1460-6.
- 568 36. Jaspal R, Kennedy L, Tariq S. Human Immunodeficiency Virus and Trans Women: A
569 Literature Review. *Transgend Health*. 2018;3(1):239-50.
- 570 37. Radix A, Sevelius J, Deutsch MB. Transgender women, hormonal therapy and HIV
571 treatment: a comprehensive review of the literature and recommendations for best practices. *J Int*
572 *AIDS Soc*. 2016;19(3 Suppl 2):20810.
- 573 38. Wansom T, Guadamuz TE, Vasani S. Transgender populations and HIV: unique risks,
574 challenges and opportunities. *J Virus Erad*. 2016;2(2):87-93.
- 575 39. Braun HM, Candelario J, Hanlon CL, Segura ER, Clark JL, Currier JS, Lake JE.
576 Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing
577 Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns. *LGBT*
578 *Health*. 2017;4(5):371-5.
- 579 40. Murray MM, Jensen A, Cieslik T, Cohn SE. Potential risk of drug-drug interactions with
580 hormonal contraceptives and antiretrovirals: prevalence in women living with HIV. *Drugs Context*.
581 2020;9.
- 582 41. Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent Tobacco Smoking is Associated with
583 Poor HIV Medical Outcomes Among HIV-Infected Individuals in New York. *AIDS and Behavior*.
584 2016;20(8):1722-9.
- 585 42. Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts DH, Gandhi M,
586 Mocharnuk RS, Anastos K. Association of Cigarette Smoking With HIV Prognosis Among
587 Women in the HAART Era: A Report From the Women's Interagency HIV Study. *American*
588 *Journal of Public Health*. 2006;96(6):1060-5.
- 589 43. Muccini C, Crowell TA, Pinyakorn S, Kroon E, Sacdalan C, Ananworanich J, Vasani S,
590 Phanuphak N, Colby DJ. Brief Report: Syphilis Incidence and Effect on Viral Load, CD4, and
591 CD4/CD8 Ratio in a Thai Cohort of Predominantly Men Who Have Sex With Men Living With
592 HIV. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2021;86(2).
- 593 44. Giltay EJ, Fonk JCM, von Blomberg BME, Drexhage HA, Schalkwijk C, Gooren LJG. In
594 Vivo Effects of Sex Steroids on Lymphocyte Responsiveness and Immunoglobulin Levels in
595 Humans. *The Journal of Clinical Endocrinology & Metabolism*. 2000;85(4):1648-57.

- 596 45. Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr Philip E, Darling K, Babouee Flury B,
597 Polli C, Sultan-Beyer L, Abela IA, Aebi-Popp K, the Swiss HIV Cohort Study. Women with HIV
598 transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS). *HIV*
599 *Medicine*. 2022;23(4):417-25.
- 600 46. Peckham H, Webb K, Rosser EC, Butler G, Ciurtin C. Gender-Diverse Inclusion in
601 Immunological Research: Benefits to Science and Health. *Front Med* 2022;9:909789.
- 602 47. Brodin P, Davis MM. Human immune system variation. *Nat Rev Immunol*. 2017;17(1):21-
603 9.
- 604 48. Pulendran B. Systems vaccinology: Probing humanity's diverse immune systems with
605 vaccines. *Proceedings of the National Academy of Sciences*. 2014;111(34):12300.
- 606 49. Lacombe-Duncan A, Bauer GR, Logie CH, Newman PA, Shokoohi M, Kay ES, Persad Y,
607 O'Brien N, Kaida A, de Pokomandy A, Loutfy M. The HIV Care Cascade Among Transgender
608 Women with HIV in Canada: A Mixed-Methods Study. *AIDS Patient Care and STDs*.
609 2019;33(7):308-22.
- 610 50. Jäggi T, Jellestad L, Corbisiero S, Schaefer DJ, Jenewein J, Schneeberger A, Kuhn A,
611 Garcia Nuñez D. Gender Minority Stress and Depressive Symptoms in Transitioned Swiss
612 Transpersons. *BioMed Research International*. 2018;2018:8639263.
- 613 51. Baker KE, Wilson LM, Sharma R, Dukhanin V, McArthur K, Robinson KA. Hormone
614 Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review.
615 *Journal of the Endocrine Society*. 2021;5(4):bvab011.
- 616 52. Hughto JMW, Gunn HA, Rood BA, Pantalone DW. Social and Medical Gender
617 Affirmation Experiences Are Inversely Associated with Mental Health Problems in a U.S. Non-
618 Probability Sample of Transgender Adults. *Archives of Sexual Behavior*. 2020;49(7):2635-47.
- 619 53. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B,
620 Bernasconi E, Rickenbach M, Günthard HF, Bucher HC, the Swiss HIV Cohort Study.
621 Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to
622 Antiretroviral Therapy: Swiss HIV Cohort Study. *JAIDS Journal of Acquired Immune Deficiency*
623 *Syndromes*. 2010;54(2).
- 624 54. Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV Infected
625 Patients: a Review. *Current Psychiatry Reports*. 2014;17(1):530.
- 626 55. Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and
627 HIV/AIDS: the need for an integrated response. *AIDS*. 2019;33(9).
- 628 56. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and Adherence to
629 Antiretroviral Therapy in Low-, Middle- and High-Income Countries: A Systematic Review and
630 Meta-Analysis. *Current HIV/AIDS Reports*. 2014;11(3):291-307.
- 631 57. de Wit AE, Booij SH, Giltay EJ, Joffe H, Schoevers RA, Oldehinkel AJ. Association of
632 Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women.
633 *JAMA Psychiatry*. 2020;77(1):52-9.
- 634 58. Kulkarni J. Depression as a side effect of the contraceptive pill. *Expert Opinion on Drug*
635 *Safety*. 2007;6(4):371-4.
- 636 59. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal
637 Contraception With Depression. *JAMA Psychiatry*. 2016;73(11):1154-62.
- 638 60. Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr PE, Darling KEA, Babouee Flury B, Polli
639 C, Sultan-Beyer L, Abela IA, Aebi-Popp K, the Swiss HIV Cohort Study. Brief Report: Does
640 Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV?
641 *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2023;92(5):399-404.

- 642 61. Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen
643 therapy on circulating inflammatory markers. *Maturitas*. 2009;62(3):281-6.
- 644 62. Scherrer AU, Traytel A, Braun DL, Calmy A, Battegay M, Cavassini M, Furrer H, Schmid
645 P, Bernasconi E, Stoeckle M, Kahlert C, Trkola A, Kouyos RD, Tarr P, Marzolini C, Wandeler G,
646 Fellay J, Bucher H, Yerly S, Suter F, Hirsch H, Huber M, Dollenmaier G, Perreau M, Martinetti
647 G, Rauch A, Günthard HF. Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). *Int J*
648 *Epidemiol*. 2022;51(1):33-4j.
- 649 63. Olink Inflammation 2019 [Available from:
650 <https://www.olink.com/content/uploads/2019/04/Olink-Inflammation-Validation-Data-v3.0.pdf>.
651

Figure 1

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.09.23289654>; this version posted May 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Figure 2

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.09.23289654>; this version posted May 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Figure 3

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.09.23289654>; this version posted May 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Figure 4

